Regeneron Pharmaceuticals (REGN) and Sanofi presented positive phase III data on Praluent in patients who underwent LDL apheresis therapy.
- PR Newswire•yesterdayAmgen Announces Positive Top-Line Results From Phase 3 Study Of Prolia® (Denosumab) In Patients Receiving Glucocorticoid Therapy
THOUSAND OAKS, Calif., Aug. 29, 2016 /PRNewswire/ -- Amgen (AMGN) today announced positive top-line results from the primary analysis conducted in a Phase 3 randomized, double-blind, double-dummy, active-controlled study evaluating the safety and efficacy of Prolia® (denosumab) compared with risedronate in patients receiving glucocorticoid treatment. "The impact of glucocorticoid therapy on bone strength is frequently underestimated, and often leads to increased bone loss and ultimately, a fracture," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||170.84 x 200|
|Ask||170.94 x 300|
|Day's Range||170.12 - 171.94|
|52wk Range||130.09 - 176.64|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||17.47|
|Avg Vol (3m)||2,901,245|
|Dividend & Yield||4.00 (2.33%)|